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Abstract Myotonic dystrophy protein kinase (DMPK) and
Rho-kinase are related. An important function of Rho-kinase is
to phosphorylate the myosin-binding subunit of myosin phospha-
tase (MYPT1) and inhibit phosphatase activity. Experiments
were carried out to determine if DMPK could function similarly.
MYPT1 was phosphorylated by DMPK. The phosphorylation
site(s) was in the C-terminal part of the molecule. DMPK was
not inhibited by the Rho-kinase inhibitors, Y-27632 and HA-
1077. Several approaches were taken to determine that a major
site of phosphorylation was T654. Phosphorylation at T654
inhibited phosphatase activity. Thus both DMPK and Rho-
kinase may regulate myosin II phosphorylation. ß 2001 Fed-
eration of European Biochemical Societies. Published by Elsev-
ier Science B.V. All rights reserved.
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1. Introduction
Myotonic dystrophy protein kinase (DMPK) is the protein
encoded by the DM-1 locus that is mutated in myotonic dys-
trophy [1,2]. The functional and structural characteristics of
DMPK [3] are related to a group of serine-threonine protein
kinases designated as the ‘myotonic dystrophy family of pro-
tein kinases’ (MDFPK) [4]. This group includes Neurospora
Cot1, Drosophila Wts, rat ROKK, human p160ROCK, human
PK418 [4], Caenorhabditis elegans LET-502, Drosophila Gen-
ghis Khan, murine Citron Rho-interacting kinase (CRIK) and
rat DM kinase-related Cdc42-binding kinase (MRCK) [5].
Several MDFPK kinases interact with members of the Rho
family of small GTPases. The Rho family includes RhoA,
Rac-1 and Cdc42; this family is functionally and structurally
related to the Ras superfamily of regulatory GTPases [6]. We
have recently shown that DMPK binds preferentially to Rac-1
of the Rho family and their coexpression results uniquely in
GTP-sensitive activation of DMPK ([5]; see also [7]).
Myosin phosphatase (MP) is composed of three subunits
[8] ; the catalytic subunit, protein phosphatase type 1, delta
isoform (PP1cN) ; and two non-catalytic subunits, of 18^21
kDa and approximately 100 kDa. The function of the smaller
subunit is not known but the larger subunit is thought to act
as a targeting subunit and bind PP1cN and myosin [8]. It is
termed MP target subunit, MYPT. There are two human
genes for MYPT [9]. MYPT1 is widely distributed and found
in smooth muscle and most non-muscle cells [8], whereas
MYPT2 is found in brain, skeletal and cardiac muscle [9].
In addition to a targeting role, MYPT1 also regulates the
activity of PP1cN. Phosphorylation of MYPT1 by an endog-
enous kinase in MP holoenzyme preparations [10] or by Rho-
associated protein kinase (Rho-kinase) ([11,12] also termed
ROKK and L, ROCK I and II and p160ROCK [13]) inhibits
phosphatase activity. A consequence of MP inhibition is to
increase the level of myosin phosphorylation and this leads to
Ca2 sensitization in smooth muscle [8] and cytoskeletal re-
arrangements (increase in stress ¢bers and focal adhesions) in
non-muscle cells [13]. The ‘inhibitory’ site of phosphorylation
for both the endogenous kinase [10] and Rho-kinase [12] is
T654 (based on the sequence of the chick M130 isoform, or
T695 for the M133 isoform [14]).
The overexpression of DMPK in cultured lens epithelial
cells induced marked rearrangements of the actin cytoskeleton
and plasma membranes [7]. These observations and the sim-
ilarity of the sequences of the catalytic domains of DMPK
and Rho-kinase [14] suggested that the two kinases may op-
erate via a common pathway. One possibility being the phos-
phorylation of MYPT1 and the inhibition of MP activity. In
this communication it is shown that DMPK phosphorylates
MYPT1 in vitro at a site also phosphorylated by Rho-kinase
and that this phosphorylation results in inhibition of PP1cN
activity.
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2. Materials and methods
2.1. Materials
Chemicals and vendors were as follows: [Q-32P]ATP (NEN Life
Science Products Inc.); ATP (Sigma); ATPQS (Calbiochem); HA-
1077, microcystin-LR (LC Laboratories) ; Rho-kinase (ROKK/
ROCK II), catalytic subunit of cAMP-dependent protein kinase
(PKA), Y-27632 (Upstate); Talon metal a⁄nity resin (Clontech); glu-
tathione Sepharose 4B (Amersham Pharmacia Biotech); nitrocellulose
membrane (0.2 Wm, Bio-Rad). All other chemicals and reagents were
of the highest grade commercially available.
2.2. Protein preparations
A catalytically active fragment of DMPK (residues 1^540) was ex-
pressed in Sf9 cells as an N-terminal polyhistidine fusion protein and
puri¢ed as described [3,5]. This construct contained the N-terminal
leucine-rich repeat, the catalytic domain and the K-helical coiled-coil
leucine zipper at its C-terminus. The full-length MYPT1 (M133 chick-
en isoform [8]) was expressed in Escherichia coli BL-21 as a gluta-
thione S-transferase (GST) fusion protein [15] and termed GST-
MYPT1. The N-terminal fragment of MYPT1 (residues 1^633) was
expressed in E. coli M15 as a hexahistidine-tagged protein [16]. The C-
terminal fragment of MYPT1 (residues 514^963; M130 chicken iso-
form [8] and termed C130514ÿ963) was prepared by the following pro-
cedure. The cDNA for C130514ÿ963 was obtained by PCR ampli¢ca-
tion directly from a chicken gizzard Uni-Zap cDNA library [17] with
Taq DNA polymerase. The forward primer was 5P-AGAAGTG-
GATCCTTTGGTAGA-3P (underlined residues show the BamHI
site), the reverse primer was 5P-TTCTCGTCGACTTCAGATATCC-
TT-3P (underlined residues show the SalI site). The PCR product was
digested with BamHI and SalI and ligated into pQE30 vector (Qia-
gen). The recombinant hexahistidine-tagged C-terminal fragment of
MYPT1 was produced in the M15 strain of E. coli as described
[16]. The T654 to A mutation (T654A) was created in the pQE30
C130514ÿ963 construct with Transformer TM site-directed mutagenesis
kit (Clontech) using 5P-TCCAGAAGATCTGCGCAGGGTGTAAC-
A-3P (underline indicates the mutated codon for the residue 654). The
mutant (termed C130514ÿ963 T654A) was selected by the concomitant
conversion of the unique AlfIII site to a BglII site and resistance to
digestion with AlfIII. The recombinant protein was expressed in E.
coli JM109 and puri¢ed as described [16].
The polyclonal site- and phosphorylation-speci¢c antibody was
raised in rabbits and a⁄nity-puri¢ed as described [12]. Other protein
preparations were as follows: PP1c from rabbit skeletal muscle [18];
the 20 kDa myosin light chain (MLC20) from turkey gizzard myosin
[19] and the 32P-labeled MLC20 [20].
2.3. Phosphorylation assays
Phosphorylation of MYPT1 fragments (100 Wg/ml) by either
DMPK (see ¢gure legends) or Rho-kinase (see ¢gure legends) was
carried out in 20 mM Tris^HCl (pH 7.5), 30 mM KCl, 5 mM MgCl2,
1 mM EGTA, 0.5 mM dithiothreitol (DTT); 1 WM microcystin-LR,
and 0.1 mM [Q-32P]ATP (150^500 cpm/pmol). Total assay volumes
ranged from 150 to 200 Wl. Aliquots (20 Wl) were removed at di¡erent
intervals, spotted onto P81 Whatman phosphocellulose paper and
washed three times in 300 ml 0.5% phosphoric acid, then with ace-
tone. Incorporation of 32P into the substrates was determined by
counting the dried P81 papers in a scintillation counter. Alternatively,
20 Wl aliquots were added to an equal volume of SDS^PAGE sample
bu¡er, boiled for 5 min and the samples were electrophoresed on 10%
SDS^PAGE mini-gels. The gels were stained, dried and subjected to
autoradiography or blotted onto nitrocellulose membrane. To deter-
mine the e¡ects of phosphorylation on phosphatase activity, phos-
phorylation of the full-length MYPT1 mutant was carried out under
similar conditions without microcystin-LR and using ATPQS instead
of ATP. The reactions were diluted (3^200-fold) with a bu¡er con-
taining 20 mM Tris^HCl (pH 7.5), 30 mM KCl, 0.2 mM DTT, 0.4
mg/ml bovine serum albumin and assayed for phosphatase activity.
2.4. Phosphatase assays
Phosphatase assays were carried out at 30‡C using 32P-labeled
MLC20 (5 WM) as substrate. The assay mixtures (30 Wl total volume)
contained approximately 3 nM PP1c prepared from rabbit skeletal
muscle and various concentrations of phosphorylated MYPT1 in 20
mM Tris^HCl (pH 7.5), 30 mM KCl, 0.2 mM DTT, 0.4 mg/ml bovine
serum albumin. Reactions were started after a 5 min incubation at
30‡C by the addition of substrate and terminated by the addition of
bovine serum albumin to 6 mg/ml and trichloroacetic acid to 10%.
The precipitated proteins were sedimented at 15 000Ug for 2 min and
the radioactivity of the supernatant was determined by Cerenkov
counting.
2.5. Other procedures
SDS^PAGE was performed using the conditions of Laemmli [21]
on Bio-Rad mini-gels of 10% polyacrylamide. Proteins from mini-gels
were transferred to nitrocellulose for 60 min at 250 mA. Non-fat dried
milk in TBS containing 0.05% Tween 20 was used for blocking the
membrane (5%) and as a carrier (1%). After blocking, the membrane
was washed and exposed to the primary antibody for 60 min at room
temperature. For detection of primary antibody, peroxidase-coupled
secondary antibody was used with enhanced chemiluminescence re-
agent (Pierce). Protein concentrations were determined with either
the BCA (Pierce) or Bradford (Bio-Rad) methods using bovine serum
albumin as standard.
3. Results
3.1. Phosphorylation of MYPT1 by DMPK
The initial experiment was to determine if MYPT1 and its
fragments are phosphorylated by DMPK. As shown in Fig.
1A the full-length MYPT1 and the C-terminal fragment of
Fig. 1. Phosphorylation of MYPT1 and its fragments by DMPK
(A) and by Rho-kinase (B). Substrates are each at 100 Wg/ml. GST-
MYPT1 (R), N-terminal fragment, residues 1^633 (b) ; C-terminal
fragment, C130514ÿ963 (F). DMPK, 10 Wg/ml; Rho-kinase, 50 mU/
ml. For other conditions see Section 2. Values are mean þ S.E.M.
(n = 3^5).
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MYPT1, C130514ÿ963, are phosphorylated by DMPK. The ¢-
nal stoichiometry of phosphorylation was about 0.6 mol P/
mol substrate. In contrast, the N-terminal fragment of
MYPT1 containing residues 1^633 was not phosphorylated
by DMPK. Similar phosphorylation pro¢les were obtained
for Rho-kinase and MYPT1 and its mutants (Fig. 1B). The
level of phosphorylation of C130514ÿ963 by Rho-kinase was
higher than for DMPK and approached 1 mol P/mol sub-
strate. Again, the extent of phosphorylation of the N-terminal
MYPT1 fragment by Rho-kinase was considerably reduced.
These results indicate that MYPT1 is a substrate for DMPK
and the major phosphorylation site(s) is located in the C-ter-
minal part of the molecule, i.e. similar to the phosphorylation
of MYPT1 by Rho-kinase.
Rho-kinase can phosphorylate the regulatory light chain of
smooth muscle myosin [22] and because of the similarity be-
tween Rho-kinase and DMPK it was important to screen
MLC20 as a substrate for DMPK. It was found that
DMPK does not phosphorylate smooth muscle MLC20
(data not shown). It was shown previously [23] that a
DMPK construct does not phosphorylate the light chain of
skeletal muscle myosin.
3.2. E¡ect of Rho-kinase inhibitors on DMPK activity
Two widely used inhibitors of Rho-kinase are Y-27632 and
HA-1077 [24] although these are not speci¢c for Rho-kinase
[25]. Because of the sequence similarity in the catalytic do-
mains of DMPK and Rho-kinase the e¡ect of these inhibitors
on DMPK activity was assayed. The results shown in Fig. 2
indicate that DMPK is not inhibited by either Y-27632 or
HA-1077 at concentrations up to 10 WM. Even at higher con-
centrations of both inhibitors (100 WM) DMPK activity was
reduced by only approximately 10% (data not shown). In
contrast, Rho-kinase is e¡ectively inhibited by these com-
pounds. Reported Ki values for Y-27632 and HA-1077 with
Rho-kinase are 0.14 and 0.33 WM, respectively [24]. These
results were obtained with C130514ÿ963, but full-length
MYPT1 yielded similar results (data not shown).
3.3. Site(s) of phosphorylation on MYPT1 for DMPK
It is established [12,22] that the sites of phosphorylation for
Rho-kinase on MYPT1 are the inhibitory site, T654 (T695 in
the longer chicken M133 isoform) and T809 (T850 in M133).
Various procedures were used to determine if the inhibitory
site in MYPT1 was also phosphorylated by DMPK.
Fig. 3 shows the e¡ect of DMPK following phosphoryla-
tion of MYPT1 with Rho-kinase. Phosphorylation with full-
length GST-MYPT1 was initiated by Rho-kinase and at 32
min either Y-27632 (12.7 WM) or Y-27632 plus DMPK were
added. The increase in phosphorylation by DMPK following
inhibition of Rho-kinase paralleled the phosphorylation pro-
¢le obtained with DMPK alone. This is consistent with phos-
Fig. 2. E¡ect of Rho-kinase inhibitors, Y-27632 (a, b) and HA-
1077 (E, F) on activities of DMPK and Rho-kinase. Conditions:
DMPK, 1.5 Wg/40 Wl (a, E) ; Rho-kinase, 5 mU/40 Wl (b, F) ; sub-
strate C130514ÿ963, 4 Wg/40 Wl. Other conditions see Section 2. Val-
ues are mean þ S.E.M. (n = 3).
Fig. 3. Phosphorylation of GST-MYPT1 and C130514ÿ963 T654A by
DMPK and Rho-kinase. GST-MYPT1 and DMPK, 1 Wg/200 Wl
(R). Sequential phosphorylation of GST-MYPT1 by Rho-kinase
and DMPK. Initial phosphorylation by Rho-kinase, 5 mU/200 Wl.
At 32 min (arrow) either Y-27632, 12.7 WM, was added (P) or Y-
27632 plus DMPK, 1 Wg/200 Wl (O). Phosphorylation of
C130514ÿ963 T654A by DMPK (F) or Rho-kinase (E). Other condi-
tions see Section 2.
Fig. 4. Protein stain, autoradiograms and Western blots of GST-
MYPT1 after phosphorylation for 1 h by DMPK, Rho-kinase, and
PKA. Lane 1, Coomassie protein stain, molecular weight markers
indicated. Autoradiograms after phosphorylation with [Q-32P]ATP by
Rho-kinase, lane 2, and DMPK, lane 3. Western blots using site-
and phosphorylation-speci¢c antibody after thiophosphorylation
with ATPQS by Rho-kinase, lane 5, DMPK, lane 6, and PKA, lane
7. Unphosphorylated GST-MYPT1, lane 4. Approximately 2 Wg
protein was loaded per lane. Other conditions see Section 2.
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phorylation of the same site by Rho-kinase and DMPK. To
determine whether T654 was a major site the T654A mutant
(C130514ÿ965 T654A, see Section 2) was used. As shown in Fig.
3 the phosphorylation of the T654A mutant by both DMPK
and Rho-kinase was considerably reduced. To con¢rm that
T654 was a major site of phosphorylation by DMPK, the
full-length GST-MYPT1 was phosphorylated using [32P]ATP
and ATPQS (Fig. 4), applied to SDS^PAGE and transferred to
nitrocellulose membrane. The protein staining pattern (Coo-
massie blue) is shown in Fig. 4, lane 1, and the major band for
GST-MYPT1 runs at approximately 160 kDa. Proteolysis
products of GST-MYPT1 are also visible. The autoradio-
grams following phosphorylation by Rho-kinase and DMPK
are shown in lanes 2 and 3 and align with the 160 kDa band.
Western blots using the T654 site- and phosphorylation-spe-
ci¢c antibody are shown in Fig. 4, lanes 5 and 6, and indicate
that T654 is phosphorylated by both Rho-kinase and DMPK.
As a control, phosphorylation of GST-MYPT1 by the cata-
lytic subunit of the cAMP-dependent protein kinase was
monitored. This showed phosphorylation via the autoradio-
gram but the signal with the speci¢c antibody was consider-
ably reduced (Fig. 4, lane 7).
These data establish that T654 is a major site of phosphor-
ylation for DMPK on MYPT1. In fact, from the results ob-
tained with the T654A mutant there is little evidence for a
second major site of phosphorylation.
3.4. E¡ect of phosphorylation of MYPT1 by DMPK on
phosphatase activity
A critical point was to determine if phosphorylation of
T654 by DMPK inhibited PP1c activity. GST-MYPT1 was
phosphorylated by DMPK for various times (the time points
indicated in Fig. 5 correspond to those shown in Fig. 1),
mixed with PP1c and phosphatase activity was assayed using
[32P]MLC20. As shown in Fig. 5 the phosphorylated GST-
MYPT1 inhibited PP1c activity. The maximum extent of in-
hibition was about 80%. The marked sensitivity of the phos-
phorylation dependence of inhibition is not understood, but
may re£ect a lower concentration of active PP1c, compared to
total protein concentration. For these experiments the stoichi-
ometry of PP1c:GST-MYPT1 was constant at about 1.5. The
inset in Fig. 5 shows inhibition of PP1c with varying amounts
of phosphorylated GST-MYPT1. At an apparent stoichiom-
etry of about 1 the inhibition was close to maximum.
4. Discussion
The data presented above show that MYPT1 is a substrate
for DMPK and its phosphorylation at T654 inhibits PP1c
activity. Designation of the inhibitory phosphorylation site
depends on the MYPT1 isoform, particularly on the presence
or absence of a central insert. For example, in the shorter
chicken MYPT1 isoform the site is T654 and for the longer
(plus sequence insert) isoform it is T695 [8]. In human
MYPT1 it is T696 [26]. However, in each isoform the se-
quence around this site is highly conserved. The sequence
G653 to T747 in the longer chicken isoform (G612 to T706
in the shorter isoform) is identical to human and porcine
MYPT1 [26,27] and is 97% identical to rat MYPT1 [28].
Even in MYPT2, the product of a di¡erent gene, the sequence
R632 to T660 is 93% identical to the chicken isoforms [9]. In
MYPT2 the phosphorylation and putative inhibitory site is
T646. Conservation of this sequence suggests that this site
has an important function and the ¢nding that several kinases
(endogenous kinase [10], Rho-kinase [12], DMPK (this study))
can phosphorylate MYPT1 and inhibit PP1c activity may in-
dicate a general regulatory mechanism, i.e. not con¢ned to
one signal transduction pathway. Activation of RhoA obvi-
ously is important for Rho-kinase activity and via inhibition
of MP is thought to be involved in Ca2 sensitization of
smooth muscle [8]. On the other hand it has been suggested
that DMPK is regulated by Rac-1 and Raf-1 kinase [5] and a
novel member of the small heat shock protein family [29] and
may re£ect a convergence of signals to regulate a common
mechanism, namely phosphorylation of myosin II. Alterna-
tively, the di¡erential localization of Rac-1 and RhoA to spe-
ci¢c regions of the cytoskeleton (6) may suggest that myosin
II phosphorylation by DMPK and Rho-kinase might be lo-
calized similarly.
In order for DMPK to in£uence MP activity it is reason-
able to expect that both DMPK and MYPT1 are expressed in
the same cell. Recently it was found that the DMPK protein is
detected mainly in skeletal and cardiac muscle and to a lesser
extent in smooth muscle [30]. Northern blot analyses also
indicate the presence of DMPK in brain [31]. For the myosin
targeting subunit both MYPT1 and MYPT2 should be con-
sidered. Northern blots for MYPT2 mRNA detected abun-
dant signals in adult human heart and skeletal muscle and a
weaker signal in brain [9]. At the protein level both MYPT1
and MYPT2 were identi¢ed in brain and heart, although in
the latter MYPT2 was the major component [9]. Full-length
MYPT1 and MYPT2 were not detected in skeletal muscle but
fragments of MYPT2 have been identi¢ed [32,33]. Thus, the
DMPK/MYPT1 pairing seems to be satis¢ed in smooth
muscle, brain and possibly cardiac muscle. In adult skeletal
muscle it is thought that the major isoform is MYPT2 and
although MYPT2 contains a conserved sequence £anking a
putative phosphorylation site it is not known if MYPT2 is
phosphorylated. Another possibility is that expression of
MYPT1 and MYPT2 varies at di¡erent stages of striated
muscle development, or di¡erentiation. In support of this
Fig. 5. Inhibition of PP1c activity following phosphorylation of
GST-MYPT1 by DMPK. The samples obtained in Fig. 1 were
used, diluted 125-fold (to 5 nM) and used in phosphatase assays
with PP1c and [32P]MLC20 (see Section 2). Inset, the 20 min time
point (from Fig. 1) was used at di¡erent dilutions in phosphatase
assays. For these assays PP1c was approximately 3 nM.
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idea it was found that MYPT1 was detected at relatively high
levels in embryonic and neonatal rat cardiomyocytes [34] and
also MYPT1 was present in C2C12 cells (Y. Wu and D.J.
Hartshorne, personal communication). The importance of
myosin light chain kinase (and hence myosin phosphoryla-
tion) in cardiac sarcomere organization has recently been
documented [35].
In summary, it is shown that MYPT1 is phosphorylated by
DMPK and that phosphorylation at T654 inhibits PP1c ac-
tivity. This situation is similar to that observed for Rho-kinase
and for the endogenous kinase present in MP holoenzyme
preparations. Inhibition of MP via phosphorylation by di¡er-
ent kinases raises the possibility that signal transduction path-
ways may converge on one mechanism controlling the cell
level of myosin phosphorylation.
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